扭亏为盈 博腾股份预计前三季度实现净利润7320万元至8820万元

Core Viewpoint - Chongqing Boteng Pharmaceutical Technology Co., Ltd. expects to achieve a net profit of 73.2 million to 88.2 million yuan for the first three quarters of 2025, marking a turnaround from losses to profits [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, of 50 million to 65 million yuan, also indicating a turnaround from losses to profits [1] - Projected operating revenue for the first three quarters of 2025 is between 2.48 billion and 2.58 billion yuan, representing a year-on-year growth of 17% to 21% [1] Business Development - The company has seen steady growth in overall business due to the continuous enrichment and expansion of its client and product pipelines, as well as improvements in research and development capabilities and product delivery [1] - The scale effect from increased operating revenue has led to a recovery in the company's profitability [1] Operational Efficiency - The company has implemented cost reduction and efficiency enhancement measures, resulting in improved operational efficiency and a continuous improvement in overall gross margin year-on-year [1]